Alto Neuroscience

NYSE: ANRO · SEC EDGAR filings

Results on file1
Average 24h move−7.39%across 1 result with a complete 24h price
1 resultAlto Neuroscience
Missed endpoint

ALTO-101

Phase 2 n=82 Schizophrenia

Alto Neuroscience ANRO

24h stock move −7.39%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.